Dry AMDVIRETTANCT07433088
Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration as Clinical Endpoints
A study testing Object recognition and selection task in people with Dry AMD and Geographic Atrophy, run by Streetlab.
Trial summary
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrialized countries and affects tens of millions of people worldwide, with a rapidly increasing prevalence. Read more about this study
- Who is it for?
- Ages 50 years and olderHealthy volunteers can take part
- Conditions the study is for
- Dry AMD, Geographic Atrophy, Healhty
- What is being tested?
- Object recognition and selection task
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- No sites listed yet
- Study dates
- Apr 2026to Apr 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age ≥ 50 years
- Sufficient knowledge of the French language
- Ability to give personal, express, free, and informed consent
- Ability to comply with the requirements of the protocol
- Person covered by Social Security
- Clarity of the ocular environment, adequate pupil dilation to allow the collection of good quality images, as determined by the investigator
Show all 23Show fewer
- Additional inclusion criteria for group 1, healthy subjects:
- No detectable visual pathologies
- Best monocular visual acuity ≥ 8/10
- Additional inclusion criteria for group 2, subjects with LMA, early AMD, or intermediate AMD without atrophy:
- Diagnosis of AMD, early AMD, or intermediate AMD
- Absence of geographic atrophy
- Presence of drusen (diameter > 63 µm) with or without pigmentary changes
- Additional inclusion criteria for group 3, subjects with dry AMD with perifoveal atrophy:
- Diagnosis of atrophic AMD
- Presence of drusen (diameter > 125 µm)
- Location of geographic atrophy as determined by the investigator: extrafoveal, juxtafoveal
- Preservation of central vision confirmed by the investigator based on a comprehensive and integrated interpretation of SD-OCT, FAF, retinography, and best corrected visual acuity examinations.
- Additional inclusion criteria for group 4, Subject with dry AMD with foveal atrophy:
- Diagnosis of atrophic AMD
- Presence of drusen (diameter > 125 µm)
- Investigator's localization of geographic atrophy: retrofoveal
- Central vision impairment confirmed by the investigator based on a comprehensive and integrated interpretation of SD-OCT, FAF, retinography, and best corrected visual acuity examinations.
Who cannot join
- Pregnant women, women in labor, or breastfeeding women
- Subjects undergoing drug treatments that may cause motor, visual, vestibular, or cognitive disorders (PSA, neuroleptics, etc.) or that could interfere with the study examinations
- Any concomitant intraocular condition in the eye being studied (e.g., glaucoma or cataract)
- Any retinal pathology that could cause retinal atrophy other than AMD (eliminate dystrophy, chronic CRSC, pachyatrophy, resorption of vitelliform material with atrophy, high myopia, etc.)
- Known systemic disease that, in the investigator's opinion, would prevent active participation in the study
- Participation in any other therapeutic study evaluating a drug.
- Subjects with cognitive impairment, illiterate subjects, and subjects who do not speak the national language.
- Persons subject to enhanced protection or legal safeguards (guardianship, trusteeship).
About this study
Official title: Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrialized countries and affects tens of millions of people worldwide, with a rapidly increasing prevalence. It causes irreversible central vision loss and significant difficulties in daily activities, impairing patients' quality of life and independence. Conventional clinical assessments, which focus on visual acuity and retinal imaging, do not fully reflect the functional impact of the disease.
Virtual reality (VR) makes it possible to create immersive, controlled environments to accurately measure functional vision and simulate real-life situations. The study proposes to develop a standardized and reproducible functional test in virtual reality that can complement conventional examinations and support clinical and industrial research.
- Conditions
- Dry AMD, Geographic Atrophy, Healhty
- Being tested
- Object recognition and selection task
- Medical subject headings
- Geographic Atrophy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Object recognition and selection taskOther
The Sight Performance Object Task (SPOT) is a virtual reality (VR) based assessment designed to measure the object recognition and selection capabilities. It functional vision by replicating the real-world challenge of "finding things" under controlled environmental conditions.
| Study group | Role | What they receive |
|---|---|---|
| Main | Experimental | Not described Receives: Other: Object recognition and selection task |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Net selection assessed by the SPOT test
Net selection is the number of selected targets, less the number of selected distractors
Measured: Baseline
Number of Net selection assessed by the SPOT test
Net selection is the number of selected targets, less the number of selected distractors
Measured: Hour 1
Number of target selection assessed by the SPOT test
Measured: Baseline
Number of target selection assessed by the SPOT test
Measured: Hour 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2026
- Study startApr 2026 (estimated)
- Primary completionApr 2027 (estimated)
- Study completionApr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dry AMDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Streetlab
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- CIL - Centre Ophtalmologique d'Imagerie et de Laser, Fondation Ophtalmologique Adolphe de Rothschild
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07433088
- Sponsor's protocol ID
- 2026-A00272-49
- Acronym
- VIRETTA
- Status last verified
- Feb 2026
- First submitted
- 11 Feb 2026
- Last updated
- 25 Feb 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration
- ClinicalTrials.gov ID
- NCT07433088
- Acronym / sponsor ID
- VIRETTA / 2026-A00272-49
- Conditions
- Dry AMD, Geographic Atrophy, Healhty
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- StreetlabIndustry (pharma, biotech, devices)
- Collaborators
- CIL - Centre Ophtalmologique d'Imagerie et de Laser, Fondation Ophtalmologique Adolphe de Rothschild
- Study start
- Apr 2026 (estimated)
- Primary completion
- Apr 2027 (estimated)
- Study completion
- Apr 2027 (estimated)
- First posted
- 25 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrialized countries and affects tens of millions of people worldwide, with a rapidly increasing prevalence. It causes irreversible central vision loss and significant difficulties in daily activities, impairing patients' quality of life and independence. Conventional clinical assessments, which focus on visual acuity and retinal imaging, do not fully reflect the functional impact of the disease.
Virtual reality (VR) makes it possible to create immersive, controlled environments to accurately measure functional vision and simulate real-life situations. The study proposes to develop a standardized and reproducible functional test in virtual reality that can complement conventional examinations and support clinical and industrial research.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Main | Experimental | Other: Object recognition and selection task |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (23 listed)
- Age ≥ 50 years
- Sufficient knowledge of the French language
- Ability to give personal, express, free, and informed consent
- Ability to comply with the requirements of the protocol
- Person covered by Social Security
Key exclusion criteria (8 listed)
- Pregnant women, women in labor, or breastfeeding women
- Subjects undergoing drug treatments that may cause motor, visual, vestibular, or cognitive disorders (PSA, neuroleptics, etc.) or that could interfere with the study examinations
- Any concomitant intraocular condition in the eye being studied (e.g., glaucoma or cataract)
- Any retinal pathology that could cause retinal atrophy other than AMD (eliminate dystrophy, chronic CRSC, pachyatrophy, resorption of vitelliform material with atrophy, high myopia, etc.)
- Known systemic disease that, in the investigator's opinion, would prevent active participation in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Object recognition and selection taskThe Sight Performance Object Task (SPOT) is a virtual reality (VR) based assessment designed to measure the object recognition and selection capabilities. It functional vision by replicating the real-world challenge of "finding things" under controlled environmental conditions. | Other | Main |
Primary outcome
Number of Net selection assessed by the SPOT test
Time frame: Baseline
Net selection is the number of selected targets, less the number of selected distractors
Number of Net selection assessed by the SPOT test
Time frame: Hour 1
Net selection is the number of selected targets, less the number of selected distractors
Number of target selection assessed by the SPOT test
Time frame: Baseline
Number of target selection assessed by the SPOT test
Time frame: Hour 1
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Dry AMD
RecruitingPhase 1/2
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
Dry Age-Related Macular Degeneration, Geographic Atrophy
Not yet recruiting
Safety and Clinical Performance of the LENTIS® MAX LS-313 MF80 Compared With the Monofocal L-313 in Cataract Patients With Late Age-Related Macular Degeneration: A Multicenter Comparative Clinical Investigation.
Cataract, AMD - Age-Related Macular Degeneration
Not yet recruiting
MacuMira Microcurrent Stimulation for Dark Adaptation in Dry Age-Related Macular Degeneration
Age-Related Macular Degeneration (AMD)
Active, not recruitingPhase 1/2
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
Geographic Atrophy
Active, not recruitingPhase 1/2
Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration
Age-Related Macular Degeneration
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Object recognition and selection task in people with Dry AMD and Geographic Atrophy, run by Streetlab.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 23 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 25 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Net selection assessed by the SPOT test (time frame: Baseline). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Feb 2026.